The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.
Is DFS an Appropriate Surrogate for OS in Early HER2+ Breast Cancer?
Leggi l'articolo originale
The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.